Polymer Therapeutics I pp 95-134

Part of the Advances in Polymer Science book series (POLYMER, volume 192)

PEGylation of Proteins as Tailored Chemistry for Optimized Bioconjugates

Chapter

Abstract

The high potential of peptides and proteins as therapeutic agents has not been fully exploited because of their common shortcomings: the only exist for a short lifetime in the body, they degrade easily in vivo and in vitro, and they cause immunological reactions. Among several proposed solutions, PEGylation, the covalent modification using polyethylene-glycol (PEG), has achieved interesting results, leading to a novel series of products that have already reached the market, while others will be available soon. In the past few years this technology, first developed for peptides and proteins, has been applied to non-peptide drugs, opening a new area of investigation that is receiving increasing interest. In this case, PEGylation allows the therapeutic application of molecules with inadequate water solubility, high toxicity, or a poor pharmacokinetic profile. This chapter describes recent achievements in PEGylation of proteins and peptides, with a special emphasis on the chemistry of conjugation, and it reports many examples from literature and from the authors' own experimental results.

PEG PEGylation PEG-protein PEG-drugs Polymer therapeutics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davis FF, Abuchowski A, Van Es T, Palczuk NC, Chen R, Savoca K, Wieder K (1978) Enzyme Eng 4:169 Google Scholar
  2. 2.
    Duncan R (2003) Nat Rev Drug Discov 2:347 Google Scholar
  3. 3.
    Kopećek J, Kopeckova P, Minko T, Lu Z (2000) Eur Pharm J Biopharm 50:61 Google Scholar
  4. 4.
    Harris JM, Chess RB (2003) Nat Rev Drug Discov 2:214 Google Scholar
  5. 5.
    Veronese FM, Morpurgo M (1999) Farmaco 54:497 CrossRefGoogle Scholar
  6. 6.
    Harris JM, Martin NE, Modi M (2001) Clin Pharmacokinet 40:539 CrossRefGoogle Scholar
  7. 7.
    Davis FF, Kazo GM, Nucci ML, Abuchowski A (1990) In: Lee VHL (ed) Peptide and protein drug delivery. Dekker, New York, p 226 Google Scholar
  8. 8.
    Nucci ML, Schorr R, Abuchowski A (1991) Adv Drug Deliv Rev 6:133 CrossRefGoogle Scholar
  9. 9.
    Russell-Jones GJ (1996) Adv Drug Deliv Rev 20:83 CrossRefGoogle Scholar
  10. 10.
    Okamoto CT (1998) Adv Drug Deliv Rev 29:215 CrossRefGoogle Scholar
  11. 11.
    Takakura Y, Mahoto Ri, Hashida M (1998) Adv Drug Deliv Rev 34:93 CrossRefGoogle Scholar
  12. 12.
    Allen TM (2002) Nat Rev Cancer 2:750 CrossRefGoogle Scholar
  13. 13.
    Bailon P, Berthold W (1998) Pharm Sci Technol Today 1:352 Google Scholar
  14. 14.
    Zaplisky S, Harris JM (1997) In: Chemistry and biological applications of polyethylene glycol. American Chemical Society, San Francisco Google Scholar
  15. 15.
    Veronese FM (2001) Biomaterials 22:405 CrossRefGoogle Scholar
  16. 16.
    Levy Y, Hershfield MS, Fernandez-Mejia C et al. (1988) J Pediatr 113:312 Google Scholar
  17. 17.
    Graham LM (2003) Adv Drug Deliv Rev 10:1293 Google Scholar
  18. 18.
    Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF (2002) Adv Drug Deliv Rev 54:547 Google Scholar
  19. 19.
    Bailon P, Palleroni A, Schaffer CA et al. (2001) Bioconjugate Chem 12:195 CrossRefGoogle Scholar
  20. 20.
    Reddy KR, Modi MW, Pedder S (2002) Adv Drug Deliv Rev 54:571 Google Scholar
  21. 21.
    Trainer PJ, Drake WM, Katznelson L et al. (2000) N Engl J Med 342:1171 CrossRefGoogle Scholar
  22. 22.
    Kinstler O, Moulinex G, Treheit M et al. (2002) Adv Drug Deliv Rev 54:477 CrossRefGoogle Scholar
  23. 23.
    Eyetech Study Group (2002) Retina 22:143 Google Scholar
  24. 24.
    Abuchowski A, Van Es T, Palczuk NC, Davis FF (1977) J Biol Chem 252:3578 Google Scholar
  25. 25.
    Manjula BN, Tsai A, Upadhya R et al. (2003) Bioconj Chem 14:464 Google Scholar
  26. 26.
    Working PK, Newman SS, Johnson J, Cornacoff JB (1997) Safety of poly(ethylene glycol) derivatives. In: Harris JM, Zalipsky S (eds) Poly(ethylene glycol) chemistry and biological applications. ACS, Washington, p 45 Google Scholar
  27. 27.
    Petrak K, Goddard P (1989) Adv Drug Deliv Rev 3:191 Google Scholar
  28. 28.
    Friman S, Egestad B, Sjovatt J, Svanvik J (1993) J Hepatol 17:48 CrossRefGoogle Scholar
  29. 29.
    Guiotto A, Canevari M, Pozzobon M, Moro S, Orsolini P, Veronese FM (2004) Bioorg Med Chem 12:5031 Google Scholar
  30. 30.
    Enzon Inc (1999) US Patent 5 985 263 Google Scholar
  31. 31.
    Applied Research System (1999) Wo Patent 9 955 376 Google Scholar
  32. 32.
    Orsatti L, Veronese FM (1999) J Bioac Comp Polymer 14:429 Google Scholar
  33. 33.
    Harris JM, Guo L, Fang ZH, Morpurgo M (1995) Seventh International Symposium On Recent Advances In Drug Delivery. Salt Lake City, USA Google Scholar
  34. 34.
    Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris JM, Veronese FM (1995) Bioconjug Chem 6:62 CrossRefGoogle Scholar
  35. 35.
    Akiyama Y, Otsuka H, Nagasaki Y, Kato M, Kataoka K (2000) Bioconjugate Chem 11:947 CrossRefGoogle Scholar
  36. 36.
    Zhang S, Du J, Sun R et al. (2003) Reactive and functional polymer 56:17 Google Scholar
  37. 37.
    Duncan R, Cable HC, Lloyd JB, Rejmanova P, Kopecek J (1984) Makromol Chem 184:1997 Google Scholar
  38. 38.
    Rejmanova P, Pohl J, Baudys M, Kostka V, Kopecek J (1984) Makromol Chem 184:2009 Google Scholar
  39. 39.
    Greenwald RB, Yang K, Zhao H, Conover CD, Lee S, Filpula D (2003) Bioconjug Chem 14:395 CrossRefGoogle Scholar
  40. 40.
    Greenwald RB, Choe YH, Conover CD, Shum K, Wu D, Royzen M (2000) J Med Chem 43:475 CrossRefGoogle Scholar
  41. 41.
    Choe YH, Conover CD, Wu D et al. (2002) J Control Release 79:55 Google Scholar
  42. 42.
    Schiavon O, Pasut G, Moro S, Orsolini P, Guiotto A, Veronese FM (2004) European J Med Chem 39:123 CrossRefGoogle Scholar
  43. 43.
    Caliceti P, Schiavon O, Sartore L, Monfardini C, Veronese FM (1993) J Bioact Biocomp Polym 8:41 Google Scholar
  44. 44.
    Esposito P, Barbero L, Caccia P et al. (2003) Adv Drug Deliv Rev 55:1279 CrossRefGoogle Scholar
  45. 45.
    Hooftman G, Herman S, Schacht E (1996) J Bioact Comp Polymer 11:135 Google Scholar
  46. 46.
    Delgado C, Francis GE, Malik F, Fisher D, Parkes V (1997) Pharm Sci 3:59 Google Scholar
  47. 47.
    Monkarsh SP, Ma Y, Aglione A et al. (1997) Anal Biochem 247:434 CrossRefGoogle Scholar
  48. 48.
    Veronese FM, Sacca B, Polverido, De Laureto P et al. (2001) Bioconjug Chem 1:62 Google Scholar
  49. 49.
    Wylie DC, Voloch M, Lee S, Liu YH, Cannon-Carlson S, Cutler C, Pramanik B (2001) Pharm Res 18:1354 CrossRefGoogle Scholar
  50. 50.
    Uze G, Lutfalla G, Mongensen (1995) J Interferon Cytokine Res 5:3 Google Scholar
  51. 51.
    Tyring SK (1995) Am J Obstet Gynecol 172:1350 CrossRefGoogle Scholar
  52. 52.
    Wang YS, Youngster S, Bausch J, Zhang R, Mcnemar C, Wyss DF (2000) Biochemistry 39:10634 Google Scholar
  53. 53.
    Enzon Inc (1999) US Patent 5 985 263 Google Scholar
  54. 54.
    Glue P, Fang JWS, Sabo R et al. (1999) Hepatology 30 (Suppl):A189 Google Scholar
  55. 55.
    Pepinsky RB, Le Page D, Gill JA et al. (2001) J Pharmac Exp Ther 297:1059 Google Scholar
  56. 56.
    Metcalf D (1986) Blood 67:257 Google Scholar
  57. 57.
    Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) Blood 88:1907 Google Scholar
  58. 58.
    Bowen S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, Eliason JF (1999) Exp Hematol 27:425 CrossRefGoogle Scholar
  59. 59.
    Eliason JF, Greway A, Tare N et al. (2000) Stem Cells 18:40 CrossRefGoogle Scholar
  60. 60.
    Maxygen Holdings Ltd (2002) Wo Patent 0 236 626 Google Scholar
  61. 61.
    Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ (1995) Pharm Res 13:996 Google Scholar
  62. 62.
    Wong SS (ed) (1991) Reactive groups of proteins and their modifying agents. In: Chemistry of protein conjugation and cross-linking. CRC Press, Boca Raton, p 13 Google Scholar
  63. 63.
    Lok S, Kaushansky K, Holly RD et al. (1994) Nature 369:565 CrossRefGoogle Scholar
  64. 64.
    Farese A, Hunt P, Macvitie TJ (1995) Blood 86:54 Google Scholar
  65. 65.
    Kuter DJ, Beeler DLl, Rosemberg RD (1994) Proc Natl Acad Sci 369:11104 Google Scholar
  66. 66.
    De-Boer RH, Roskos LK, Cheung E et al. (2000) Growth Factors 18:215 Google Scholar
  67. 67.
    Guerra PI, Acklin C, Kosky AA, Davis JM, Treuheit MJ, Brems DN (1998) Pharm Res 15:1822 CrossRefGoogle Scholar
  68. 68.
    Chawla RK, Parks JS, Rudman D (1983) Annu Rev Med 34:519 CrossRefGoogle Scholar
  69. 69.
    Clark R, Olson K, Fuh G, Marian M et al. (1996) J Biol Chem 271:21969 Google Scholar
  70. 70.
    Frohman LA, Jansson JO (1986) Endocr Rev 7:223 CrossRefGoogle Scholar
  71. 71.
    Lance VA, Murphy WA, Sueiras-Diaz J, Coy DH (1984) Biochem Biophys Res Commun 119:265 CrossRefGoogle Scholar
  72. 72.
    Piquet G, Gatti M, Barbero L, Traversa S, Caccia P, Esposito P (2002) J Chrom A944:141 CrossRefGoogle Scholar
  73. 73.
    D'Antonio M, Louveau I, Esposito P, Bartolino M, Canali S (2004) Growth Horm Igf Res 14:226 Google Scholar
  74. 74.
    Ares Trading Sa (2002) Wo Patent 0 228 437 Google Scholar
  75. 75.
    Goffin V, Bernichtein S, Carriere O, Bennett WF, Kopchick JJ, Kelly PA (1999) Endocrinology 140:3853 CrossRefGoogle Scholar
  76. 76.
    Parkinson C, Scarlett JA, Trainer PJ (2003) Adv Drug Deliv Rev 55:1303 CrossRefGoogle Scholar
  77. 77.
    King DJ (1998) Preparation, structure and function of monoclonal antibodies. In: Application and engineering of monoclonal antibodies. Taylor and Francis, London, p 1 Google Scholar
  78. 78.
    King DJ, Adair JR (1999) Curr Opin Drug Discov Dev 2:110 Google Scholar
  79. 79.
    Walsh G (2000) Nat Biotechnol 18:831 CrossRefGoogle Scholar
  80. 80.
    Chapman AP (2002) Adv Drug Deliv Rev 54:531 CrossRefGoogle Scholar
  81. 81.
    Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G (2000) Int J Pharm 198:83 CrossRefGoogle Scholar
  82. 82.
    Anderson WL, Tomasi TB (1988) J Immunol Methods 109:37 CrossRefGoogle Scholar
  83. 83.
    Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) J Control Release 65:271 Google Scholar
  84. 84.
    Takashina K, Kitamura K, Yamaguchi T et al. (1991) J Cancer Res 82:1145 Google Scholar
  85. 85.
    Pedley RB, Boden JA, Boden R, Dale R, Begent RH (1994) Br J Cancer 70:521 Google Scholar
  86. 86.
    Wen X, Wu Qp, Lu Y, Fan Z, Charnsangavej C, Wallace S, Chow D, Li C (2001) Bioconjug Chem 12:545 CrossRefGoogle Scholar
  87. 87.
    Old LJ, Welt S (2003) US Patent 2003 031 671 Google Scholar
  88. 88.
    Immunomedics Inc (1997) US Patent 5 670 132 Google Scholar
  89. 89.
    Hinds KD, Kim SW (2002) Adv Drug Deliv Rev 54:505 CrossRefGoogle Scholar
  90. 90.
    Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA (2002) J Control Release 80:259 Google Scholar
  91. 91.
    Amgen Inc (2003) US Patent 6 586 398 Google Scholar
  92. 92.
    Amgen Inc (2002) US Patent 6 420 339 Google Scholar
  93. 93.
    Hoffman La Roche (2000) US Patent 6 025 324 Google Scholar
  94. 94.
    Applied Research System (1999) Wo Patent 9 955 377 Google Scholar
  95. 95.
    Bolder Biotechnology Inc (1999) Wo Patent 9 903 887 Google Scholar
  96. 96.
    Smith KA (1988) Science 240:1169 Google Scholar
  97. 97.
    Goodson RJ, Katre NV (1990) Biotechnology 8:343 Google Scholar
  98. 98.
    Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ (1999) Nat Biotechnol 17:780 CrossRefGoogle Scholar
  99. 99.
    Eistein Coll Med (1996) US Patent 5 585 484 Google Scholar
  100. 100.
    Sato H (2002) Adv Drug Deliv Rev 54:487 CrossRefGoogle Scholar
  101. 101.
    Gorman JJ, Folk JE (1980) J Biol Chem 255:1175 Google Scholar
  102. 102.
    Mcdonagh RP et al. (1981) Febs Lett 127:174 CrossRefGoogle Scholar
  103. 103.
    Sato H, Hayashi E, Yamada N, Yatagai M, Takahara Y (2001) Bioconjugate Chem 12:701 CrossRefGoogle Scholar
  104. 104.
    Neose Technologies Inc (2004) US Patent 2004 132 640 Google Scholar
  105. 105.
    Chen T, Small DA, Wu LQ, Rubloff GW et al. (2003) Langmuir 19:9382 Google Scholar
  106. 106.
    Lewinska M, Seitz C, Skerra A, Schmidtchen FP (2004) Bioconjug Chem 15:231 CrossRefGoogle Scholar
  107. 107.
    Zalipsky S, Menon-Rudolph Hydrazine S (1998) Derivatives 0f poly(ethylene glycol) and their conjugates. In: Harris JM (ed) Poly(ethylene glycol) chemistry: biotechnical and biomedical applications, 2nd edn. Plenum, New York, p 319 Google Scholar
  108. 108.
    Saxon E, Bertozzi CR (2000) Science 287:2007 CrossRefGoogle Scholar
  109. 109.
    Cazalis CS, Haller CA, Sease-Cargo L, Chaikof EL (2004) Bioconjug Chem 15:1005 CrossRefGoogle Scholar
  110. 110.
    Murad KL, Mahany KL, Kuypers FA, Brugnara C, Eaton JW, Scott MD (1999) Blood 93:2121 Google Scholar
  111. 111.
    Scott MD, Chen AM (2004) Transfusion clinique et biologique 11:40 Google Scholar
  112. 112.
    Abuchowski A, Mccoy R, Palczuk NC, Van Es T, Davis FF (1977) J Biol Chem 252:3582 Google Scholar
  113. 113.
    Greenwald RB (2001) J Control Release 74:159 Google Scholar
  114. 114.
    Greenwald RB, Conover Cd, Choe Yh (2000) Crit Rev Ther Drug Carr Syst 17:101 Google Scholar
  115. 115.
    Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J, Wu G, Kneller S, Davies J, Duncan R (2005) Bioconjug Chem 16:775 CrossRefGoogle Scholar
  116. 116.
    Andersson L, Davies J, Duncan R, Ferruti P, Ford J, Kneller S, Mendichi R, Pasut G, Schiavon O, Tsirk A, Veronese FM, Vincenzi V, Wu G (2005) Biomacromol 6:914 Google Scholar
  117. 117.
    Genentech Inc (2000) US Patent 6 057 292 Google Scholar
  118. 118.
    Maeda H, Ueda M, Morinaga T, Matsumoto T (1985) J Med Chem 28:455 CrossRefGoogle Scholar
  119. 119.
    Duncan R, Kopeckova-Rejmanova P, Strohalm J, Hume I, Cable HC, Pohl J, Lloyd JB, Kopecek J (1987) Br J Cancer 55:165 Google Scholar

Copyright information

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesUniversity of PaduaPadovaItaly

Personalised recommendations